⭐ OEM Business Case
Replace Fragmented Stacks With One Rehostable Engine
Why OEM Roadmaps Stall
Traditional platforms scale by adding hardware: channels, optics, thermal zones, pumps, or modality-specific instruments. That increases complexity, cost, and time-to-menu—especially when you need high-plex or multi-class panels.
- New panels often require new hardware constraints or new workflows
- Multi-omic portfolios require multiple instruments and validation paths
- Complex matrices increase sample prep burden and cost
- Manufacturing + service burden grows with hardware complexity
What Guanine Enables
Guanine lets OEM partners keep ownership of their biomarker IP while deploying on a universal architecture—configuring panels and multiplexing behavior in software rather than rebuilding instruments.
- OEM-controlled deployments on a universal architecture
- Rehost biomarker panels without rebuilding the reader stack
- Lower complexity scaling (fewer hardware bottlenecks)
- Faster iteration cycles from assay to product menu
The goal is simple: expand assay capability and menu velocity while reducing platform complexity and long-term cost of ownership.
⭐ From Biomarker to Menu
A Clear Workflow for Assay Developers and Commercial Teams
For assay teams: pre-conjugate tags to magnetic particles, run a cartridge, and decode targets in software. For business teams: a faster path from biomarker assets to commercial assay menus—without rebuilding instrument stacks.
Assay-Developer View
- Use a universal tag + magnetic particle workflow across target types
- Expand panels through software-defined multiplexing behavior
- Keep workflows simple for mobile/POC and complex matrices
Business-Builder View
- Accelerate menu growth without manufacturing bottlenecks
- Reduce platform fragmentation across product lines
- Support multiple revenue streams (instruments, cartridges, software, OEM licensing)
⭐ OEM Product Platforms
Build Next-Generation Diagnostics on One Architecture
Develop full assay portfolios without lasers, optics, pumps, thermal cycling, or modality-specific stacks—shortening development cycles and improving capital efficiency while expanding multiplex and matrix compatibility.
2. Small-Volume Platform
3. Extreme-Plex Platform
4. Multi-Omic Platform
5. Complex Matrices Platform
6. Multi-Omic High-Plex Platform
⭐ Precision Health AI
The Diagnostic Data Layer AI Has Been Waiting For
Precision health and clinical AI systems are no longer limited by algorithms—they are limited by data. Most models are trained on sparse, single-omic, or proxy measurements that fail to capture biology in real time.
Guanine provides a single platform capable of generating high-plex, quantitative, multi-omic measurements—including proteins, nucleic acids, metabolites, redox states, and cellular responses—from the same sample.
Key advantages for AI-driven health:
- High-plex, multi-omic data from a single assay
- Quantitative signals suitable for model training and inference
- Longitudinal measurement without platform changes
- Consistent data generation across POC, lab, and high-throughput formats
- Lower cost per feature, enabling population-scale deployment
Guanine transforms diagnostics from a bottleneck into a scalable sensing layer for precision health AI—supporting earlier detection, better stratification, and continuously learning care pathways.
⭐ Pharmaceutical Diagnostics
Enabling Faster, Smarter Clinical Trials, CDx, and TDM
Drug development increasingly depends on diagnostics—not only to select patients, but to understand therapeutic response across development and clinical use. Yet many pharma diagnostic stacks remain slow, narrow, and fragmented.
Guanine delivers integrated multi-omic measurement and functional assessment from a single platform—supporting biomarker discovery, patient stratification, and therapy monitoring across the drug lifecycle.
Clinical Trials & Translational Research
- Multi-omic biomarker panels on one platform
- Longitudinal monitoring without platform changes
- Earlier pharmacodynamic and response signals
- Improved subgroup identification and trial efficiency
Companion Diagnostics (CDx)
- High-plex panels aligned to complex mechanisms of action
- Scalable expansion as biomarkers evolve
- Single platform across development, validation, and deployment
Therapeutic Drug Monitoring (TDM)
- Real-time response indicators alongside exposure
- Support for narrow therapeutic index drugs
- Potential integration of exposure, response, and resistance markers
Across trials, CDx, and TDM, Guanine provides a unified diagnostic engine—reducing complexity and accelerating development timelines.
⭐ Multiple Instrument Configurations
One Sensing Architecture, Many Deployment Modes
Guanine’s electrochemical engine scales from point-of-care cartridges to high-throughput lab automation and fully inline industrial monitoring—while keeping the same core chemistry and multiplex decoding approach.
Compact Reader + Cartridge
- Rapid, low-cost decentralized testing
- POC, near-patient, field, and low-infrastructure settings
- High value where speed and simplicity dominate
High-Throughput + Inline Modes
- Parallel processing and automation for labs (96–384 compatible)
- OEM scale-up paths for clinical + translational workflows
- Inline sampling + continuous sensing for industrial/bioprocess monitoring